Last reviewed · How we verify
NCT06977971: RADAR
RSV Antibiotic Drivers And Resource-use
trial in Respiratory Syncytial Virus Infections in 209 participants. Completed in 1 October 2023.
1 April 2021
Quick facts
| Lead sponsor | Dr. Behcet Uz Children's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 209 |
| Start date | 1 April 2017 |
| Primary completion | 1 April 2021 |
| Estimated completion | 1 October 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Respiratory Syncytial Virus Infections — all drugs for Respiratory Syncytial Virus Infections →
- Antibiotic Stewardship in Community Hospitals — all drugs for Antibiotic Stewardship in Community Hospitals →
Sponsor
Dr. Behcet Uz Children's Hospital
Who can join
Adults 1 Month to 24 Months, any sex, with Respiratory Syncytial Virus Infections or Antibiotic Stewardship in Community Hospitals. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study retrospectively evaluated the clinical, laboratory, and radiologic factors that influence the decision to prescribe antibiotics in children under 2 years of age hospitalized with RSV-positive acute lower respiratory tract infections. The study also examined the economic impact of antibiotic use in these patients. The goal is to improve clinical decision-making and reduce unnecessary antibiotic exposure in children with viral infections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06977971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Syncytial Virus Infections
Currently open trials in the same condition.
- NCT07214571 — A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of · Phase 2 · recruiting
- NCT07220109 — A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 5 · Phase 3 · recruiting
- NCT07239583 — Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) · recruiting
- NCT07092865 — A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and th · Phase 2 · recruiting
- NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
Other Dr. Behcet Uz Children's Hospital trials
Trials by the same sponsor.
- NCT06965400 — Comparison of Automatic and Manual Endotracheal Tube Cuff Pressure Monitoring in Pediatric Intensive Care Patients · NA · completed
- NCT06803355 — Comparison of Congenital Pneumonia and Transient Tachypnea of the Newborn · completed
- NCT06586411 — Comparison of Oxygenation Index and Oxygen Stretch Index · completed
- NCT06621641 — Nurse-led High-flow Nasal Cannula Weaning Protocol in Pediatric Intensive Care Unit · NA · completed
- NCT07273487 — Nurse Education to Reduce Patient-Ventilator Asynchrony in the PICU · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06977971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Behcet Uz Children's Hospital
- Last refreshed: 23 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06977971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing